Investment reaffirms business potential – or does it?

July sees an investment of $1 million (10% equity stake) by China-based Acebright Pharmaceuticals in immunotherapy developer NasVax (see the October 2, 2012 LRTJ). While this cash injection is vital for NasVax in furthering its pipeline as well as boosting investor confidence since partners such ...

This research is archived and therefore no longer available. For further assistance please contact your Customer Success Manager or email ClientEngagementTeam@luxresearchinc.com. Thank you!

Related Research

Singaporean precision medicine startup Hummingbird Bioscience nets $125 million in Series C funding led by Novo Holdings

News Commentary | May 24, 2021

This will further expand Hummingbird's proprietary Rational Antibody Discovery (RAD) platform for novel therapeutic monoclonal antibodies. The market for therapeutic antibodies is rapidly growing, as new drugs have been approved for treating various human diseases, including many cancers and ... Not part of subscription

Pfizer will acquire Trillium Therapeutics for $2.26 billion, seeking to further boost its capabilities in oncology

News Commentary | August 27, 2021

Trillium is a developer of a novel immunotherapy solution that targets a molecule called CD47 on cancer cells. In healthy cells, CD47 plays a part in displaying a "don't‑eat‑me" signal to the immune system. Malignant cancer cells display these molecules on their surface to evade the immune system. ... Not part of subscription

Genevant enters partnership with Takeda for developing rare liver disease therapies

News Commentary | September 08, 2021

Genevant Sciences develops lipid nanoparticle (LNP) nucleic acid delivery techniques, which can be utilized for mRNA‑based applications including vaccines, protein production, and nonviral gene therapies. The two companies reached an agreement for Genevant to develop therapeutics for two undisclosed... Not part of subscription